~~<i id='2F6AFB474F'><strike id='2F6AFB474F'><tt id='2F6AFB474F'><pre id='2F6AFB474F'></pre></tt></strike></i>~~

Home» leisure time» fashion

fashion

author：entertainment 2025-09-06 05:45:10 Page View：273

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Listen: Biogen's potential pivot, & Illumina's next chapter
Next article： Heart attack and stroke risk calculators need revising

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Inari Medical to buy amputation prevention company LimFlow

Inariwillpay$250millionupfrontand$165moredependingonLimFlow’scommercialsuccess.DavidGregory&Debb

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

The 10 drugs up first for Medicare price negotiation

PresidentBiden'sWhiteHouseannouncedthefirst10medicinesthatwillbeupfirstinitsnewdrugpricenegotiationp